Trial Profile
A Prospective Observational Study Conducted in France to Describe Routine Clinical Practice for Treatment naïve or Previously Treated Patients With Diabetic Macular Edema (DME) Who Are Starting IVT Aflibercept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms APOLLON
- Sponsors Bayer
- 02 Dec 2019 Status changed from active, no longer recruiting to completed.
- 30 Mar 2018 Planned primary completion date changed from 15 Sep 2019 to 15 Jul 2019.
- 03 Aug 2017 Status changed from recruiting to active, no longer recruiting.